cytokine IL-18. It effectively blocks IL-18 by forming a 1:1 high affinity (K d =400 pM) complex, exhibiting a very low dissociation rate. We have developed a sandwich ELISA for IL-18BPa and determined its limit of detection (62 pg/ml). Interference by IL-18 and related cytokines, as well as cross reactivity with other IL-18BP isoforms (b, c, and d) were determined. Using this ELISA, we measured serum IL-18BPa in large cohorts of healthy individuals and in septic patients. Serum IL-18BPa in healthy individuals was 2.15 0.15 ng/ml (range 0.5-7 ng/ml). In sepsis, the level rose to 21.9 1.44 ng/ml (range 4-132 ng/ml). Total IL-18 was measured in the same sera by an electrochemiluminescence assay and free IL-18 was calculated based on the mass action law. Total IL-18 was low in healthy individuals (64 17 pg/ml) and most of it (85%) was in its free form. Total IL-18 and IL-18BPa were both elevated in sepsis patients upon admission (1.5 0.4 ng/ml and 28.6 4.5 ng/ml, respectively). At these levels, most of the IL-18 is bound to IL-18BPa, however the remaining free IL-18 is still higher than in healthy individuals. We conclude that IL-18BPa considerably inhibits circulating IL-18 in sepsis. Yet, exogenous administration of IL-18BPa may further reduce circulating IL-18 activity.
Measurement of circulating cytokines in health and disease provides information about the process and progression of diseases in terms of severity, effects of therapy, as well as indicators of mortality and survival. Several studies reported circulating levels of the cytokine interleukin-18 (IL- 18) 1 in health and in various diseases. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] However, in any study on the role of a particular cytokine associated with a disease, concurrent measurement of naturally occurring, specific inhibitors of that cytokine is desirable. In the case of the assessing the role of IL-18 in disease, such naturally occurring inhibitor is the IL-18 binding protein (IL-18BP).
14 IL-18BP belongs to a growing family of soluble binding proteins (osteoprotegerin and cytokine-like factor-1), 15, 16 which are not variants of their cell bound receptors. Its major splice variant IL-18BPa is a unique, constitutively secreted protein, which binds IL-18 thus blocking its biological activity. Although the binding of IL-18 to IL-18BPa is highly specific, it is structurally unrelated to the two components of the cell-bound IL-18 receptor (IL-18R) complex, IL-18R and IL-18R . 17, 18 Furthermore, the binding of IL-18BPa to IL-18 exhibits an exceptional high affinity of 400 pM. 19 Hence the evaluation of IL-18 levels in the circulation must take into account the levels of IL-18BPa in the same blood sample in order to obtain a correct measurement of the IL-18. In the present study, an ELISA specific for the measurement of IL-18BPa was developed and validated. The extent of interference of IL-18 in the IL-18BPa ELISA and the interference of IL-BPa in measurements of IL-18 was evaluated. Levels of total IL-18 and IL-18BPa were measured in sera of healthy subjects and patients with sepsis syndrome accompanied by acute renal failure. Based on these values the level of free IL-18 was calculated in these sera.
RESULTS

Screening and characterization of hybridomas for anti-rIL-18BPa-His 6 positive clones
Hybridomas secreting anti rIL-18BPa-His 6 were screened by IRIA in which goat anti-mouse antibodies were used to capture the antibodies in the hybridoma supernatants and 125 I-rIL-18BPa-His 6 was used for detection. Representative hybridomas are shown in Table 1 . Hybridomas secreting antibodies directed against the histidine tag (data not shown) were discarded. Antibodies were further characterized by solid phase RIA for their ability to recognize the naturally occurring IL-18BPa. For this purpose, urinary IL-18BP served as a capture step of the sRIA and 125 I-goat anti-mouse antibody was used for detection. Binding features of several positive hybridomas are shown in Table 1 . Hybridomas no. 148, 430, 460 and 582 were positive in both assays. This fusion yielded antibodies suitable for Western blotting, immunoprecipitation, immunoaffinity purification (data not shown) and for the coating step in ELISA of IL-18BPa and the detection step of ELISA 2. Monoclonal antibody (MAb) pairs for double MAb ELISA were not obtained. Therefore, an additional fusion was performed, but this time with a spleen and lymph nodes from a mouse injected with rIL-18BPa, which was immunopurified on Mab no. 582.10 obtained from the first fusion.
Screening and characterization of hybridomas for positive anti-rIL-18BPa clones
Hybridoma supernatants were screened by sRIA, in which highly purified rIL-18BPa was used to capture the hybridoma supernatants and 125 I-goat anti-mouse antibodies were used for detection (Table 2 ). Positive clones were further analyzed by sRIA with urinary IL-18BP (Table 2) . Antibodies from both fusions were tested by sRIA in the presence of IL-18 for their ability to recognize a complex of IL-18BPa with IL-18 (see: sRIA for blocking antibodies in Methods). Most antibodies from the first fusion (Table 1 ) and antibody no. 687 from the second fusion (Table 2) were unable to recognize IL-18BP when present as a complex with IL-18 (data not shown). These antibodies are directed against the ligand-binding domain of IL-18BPa. Anti-rIL-18BPa-His 6 antibody no. 582.10 and anti rIL-18BPa antibody no. 657.27 were the most suitable for capturing IL-18BPa in the two enzyme linked immunoabsorbent assay (ELISA) procedures. They were also found to be a pair in a double antibody ELISA 2 (see Methods).
A double antibody ELISA for IL-18BPa
Two types of ELISA were developed: ELISA 1 consisted of two anti-rIL-18BP-His 6 antibodies: MAb 582.10 as the capture antibody and rabbit polyclonal antibody for detection. ELISA 2 consisted of anti-rIL18BPa MAb 657.27 as the capture antibody and a biotinylated anti-rIL-18BPa-His 6 MAb 582.10 as the detector antibody. A highly purified recombinant human rIL-18BPa, quantitated by amino acid analysis, was used as a standard in both ELISAs. Using ELISA 1, a linear standard curve was obtained between 0.062 ng/ml and 2 ng/ml (Fig. 1) . The data presented in this study were generated with ELISA 1. Representative serum samples with high and low IL-18BPa levels were also analyzed by ELISA 2. Differences between respective values were within 10%. The IL-18BPa standard curve yielded identical results in the absence of serum or in the presence of up to 20% human serum. Since IL-18BPa binds IL-18 with a very high affinity, it was necessary to determine whether ELISA 1 distinguishes between free and bound IL-18BPa. We found that IL-18 interferes with the IL-18 ELISA, however, the interference is insignificant in serum samples. In 90% of sepsis patients serum IL-18 was below 4 ng/ml (see below). Such sera have elevated IL-18BPa, requiring a five to 20-fold dilution prior to measuring IL-18BPa. At such dilutions, IL-18 interference with the IL-18BPa ELISA is less than 10% (Fig. 2) . Other related cytokines, including proIL-18, used at a 10-fold molar excess over IL-18BPa, as well as 200-fold excess of mature IL-1 did not interfere with the assay.
Cross reactivity of the IL-18BPa ELISA 1 with other IL-18BP splice variants
Judging by RNA blotting and by the relative abundance of cDNA clones, the most abundant isoform of human IL-18BP is IL-18BPa, 14, 19 whereas isoforms b, c and d are minor splice variants. IL-18BPa exhibits the highest affinity for IL-18. The affinity of IL-18BPc for IL-18 is 10-fold lower, whereas isoforms b and d lack the ability to bind or neutralize IL-18. It was therefore important to determine the crossreactivity of IL-18BPa ELISA with the other isoforms of IL-18BP. As shown in Figure 3 , human IL-18BPc gave a 10-fold lower signal on a weight basis compared with huIL-18BPa, whereas human isoforms b and d gave practically no signal in the ELISA. The two murine IL-18BP isoforms c and d 14, 19 were non-reactive with ELISA 1 even at a 1000 fold higher concentration compared with human IL-18BPa. Recombinant human IL-18BPa was serially diluted and subjected to ELISA 1 as described in Materials and Methods. Data show the mean absorbance SE of 10 experiments. ELISA was done with IL-18BPa at l or 2 ng/ml, with increasing concentrations of human IL-18. Percent inhibition of the absorbance signal is shown. The IL-18BPa ELISA was performed with all isoforms (a-d) of IL-18BP. Stocks (3.2 g/ml) of the IL-18BP isoforms were serially diluted and tested in IL-18BPa ELISA 1.
Levels of serum IL-18BPa and IL-18 in healthy individuals
We measured the level of IL-18BPa in the sera of healthy individuals (n=107). The levels ranged from 0.5 ng/ml to as high as 7 ng/ml, with an average of 2.15 0.15 ng/ml (Fig. 4) . No statistically significant correlation was found between age (20-60 years) gender and serum IL-18BPa. However, a study on a larger cohort is required in order to determine the correlation of serum IL-18BPa with age. The level of IL-18BPa in EDTA-treated plasma was about l.5-fold higher than that of its matching serum, as tested in 15 samples.
The mean level of IL-18 in healthy donors was 64 17 pg/ml as measured by the electrochemiluminescence (ECL) assay. The ECL assay was tested for interference by related proteins. We found that it was not affected by the presence of mature IL-l or proILl , whereas proIL-18 was cross-reactive. Therefore, as much as 20% of the detected mature IL-18 in human serum samples in the present study may be proIL-18. The ECL assay of IL-18 was not affected by IL-18BPa at a concentration c160 ng/ml.
Levels of total and free IL-18 in healthy individuals
Because both IL-18 and IL-18BPa are concomitantly present in the serum, some of the IL-18 may be present in a complex with IL-18BPa. We calculated the average level of free IL-18 based on the average level of total IL-18BPa (2.15 ng/ml). Accordingly, at low levels seen in healthy individuals, most of the IL-18 (85%) is calculated to be in its free form.
Levels of total and free IL-18 and IL-18BPa in humans with sepsis and acute renal failure
Levels of IL-18 and IL-18BP were tested in 192 sera samples from 42 septic patients upon admission and during hospitalization. Compared with healthy individuals, the levels of both the cytokine and the binding protein were markedly elevated (Fig. 5A) , and a broad distribution of the values was observed (Fig.  5B) . Specifically, total IL-18 in all samples ranged from 0.015-10 ng/ml with an average of 1.1 0.11 ng/ml, and IL-18BP ranged from 4-132 ng/ml with an average of 21.9 1.44 ng/ml (Fig. 5B) . Moreover, these levels were even higher in these patients at the day of admission, showing a 22-fold increase in the level of IL-18 compared with healthy individuals (1.5 0.4 ng/ml vs 0.064 17 ng/ml, respectively), and a 13-fold increase in the level of IL-18BPa (28.6 4.5 vs 2.15 0.15 ng/ml, respectively, Fig. 5A ). No significant correlation was seen between serum IL-18 and IL-18BPa and between serum IL-18 and APACHE II score (data not shown). Additionally, there was no statistically significant correlation between creatinine levels and either IL-18 or IL-18BPa concentrations in these sera (data not shown), suggesting that the elevated IL-18 and IL-18BPa levels in these patients were not due to renal failure.
Because serum IL-18 and IL-18BPa in sepsis patients varied considerably (Fig. 5B) , it was of interest to calculate the levels of free serum IL-18 in individual samples. Using the parameters described in the Methods for the calculation of free IL-18, it was found that in most patients, circulating IL-18BPa reduced the level of free IL-18. This effect was particularly noticeable when total IL-18 was very high (Fig. 6 ). For example, in two patients, serum IL-18 reached 0.5 nM (10 ng/ml), a 150-fold increase over healthy individuals. Yet, when considering binding to the circulating IL-18BPa (27 ng/ml and 41.2 ng/ml), the level of free IL-18 in those two patients dropped by 78% and 84%, respectively (Fig. 6) . As the case with total IL-18, no statistically significant correlation was seen between free IL-18 and the APACHE II score (data not shown).
DISCUSSION
The present study describes the development of an ELISA for the measurement of IL-18BPa. Before embarking on a study of IL-18BPa levels in patients with various diseases, it was necessary to determine the effect of IL-18 on the IL-18BPa ELISA measurements in human sera. In addition, it was necessary to determine the effect of IL-18BPa on IL-18 detection in the ECL assay. As described above, due to the dilution needed for performing the assay, there was no interference of IL-18 in the IL-18BP ELISA in any of the sera Sera of male and female healthy individuals, ages 20-60, were subjected to the IL-18BPa ELISA 1 (n=107).
that we have tested. In a similar fashion, there was no effect of IL-18BPa added to the IL-18 standards at concentrations as high as 160 ng/ml. Since sera were diluted twofold for the IL-18 ECL assay, measurements of IL-18 in the presence of IL-18BPa are also likely valid. Using this new ELISA, the level of total IL-18BPa was determined in large cohorts of healthy individuals and in sepsis patients. We found that serum IL-18BPa levels are elevated in sepsis and on a molar basis, these levels are 10-30 times higher than those of IL-18 in the same sera.
Since IL-18BPa is excreted in the urine, it was also important to determine the effect of renal function on the levels of IL-18BPa during disease. Renal function is often compromised in patients with sepsis, lupus nephritis, Wegener's granulomatosis and other autoimmune diseases. Therefore, we specifically examined sera from patients with sepsis and acute renal failure. IL-18BPa levels were measured and correlated to creatinine levels at entry into the study, as well as in each of the 198 sera. There was no evidence that IL-18BPa or IL-18 in these sera was elevated in association with elevated creatinine levels. Thus, we conclude that the markedly elevated levels of IL-18 and IL-18BPa levels in septic patients reflects increased production and not renal retention.
In our previous studies 14, 19 we have shown that IL-18BPa exhibits a high affinity for its ligand (K d =0.4 nM). This high affinity is mainly due to a very low dissociation rate of their 1:1 complex. Therefore, IL-18BPa is a potent inhibitor of IL-18 and does not serve as a carrier protein. The presence of relatively high levels of IL-18BPa in the serum suggest that in the circulation IL-18 is present at least in part as an inactive complex with IL-18BPa. Therefore, it was necessary to measure the level of serum IL-18BPa and take it into account in order to calculate the actual level of free IL-18 in the circulation. Indeed, in sepsis patients, we observe several cases in which most of the serum IL-18 is blocked by the circulating IL-18BPa. Yet, according to these calculations, the remaining free IL-18 is still higher than that found in healthy individuals. Therefore, it will be of interest to see if exogenous administration of IL-18BPa will further lower both tissue concentration of IL-18 and the levels of the free circulating IL-18 and whether the disease outcome will be affected. Unlike the study of Endo and co-workers, 4 in the present study the elevated levels of IL-18 measured in sera from patients with sepsis and acute renal failure did not correlate in a statistically significant fashion with the APACHE II score. The difference in the results obtained may stem from the limited group of 13 patients of the Endo study compared with the group of 42 patients in the present study. In general, the cytokine that consistently correlates with APACHE II and other score of clinical severity is IL-6, not TNFnor IL-1 . 20 . Similar to our findings, in the study of Grybmayer et al., levels of IL-18 were elevated in nine subjects with sepsis during the first 96 h following admission and did not correlate with creatinine levels. 7 In that study, IL-18 levels also did not correlate with clinical assessment scores similar to the APACHE II score used in the present study.
To our knowledge, this is the first report calculating significant cytokine inhibition by its circulating binding protein. It should, however, be noticed that most other known soluble receptors have a rather low affinity for their ligand. Therefore, at physiological concentrations, these soluble receptors serve mainly as carrier proteins, enhancing rather than inhibiting their respective cytokine. The high affinity of IL-18BPa to its ligand and the very low dissociation rate of their complex suggest that IL-18BPa does not serve as a carrier protein.
IL-18 induces IFN-and the latter was recently reported to induce IL-18BPa mRNA in vitro. 21 Therefore, IL-18BPa probably serves as a shut off signal terminating the inflammatory response. Our previous studies demonstrated effective inhibition of IFN-production by IL-18BPa in LPS-treated mice.
14 These findings confirm the antagonistic nature of IL-18BPa. Further studies on the regulation of IL-18BPa production and on the effects of its exogenous administration on free IL-18 and on various inflammatory responses are warranted. These studies will be facilitated by the availability of the present IL-18BPa ELISA.
MATERIALS AND METHODS
IL-18, IL-18BP and polyclonal antibodies
Human IL-18 was prepared in Escherchia coli as a mutated pro IL-18 fused to Glutathione-S-transferase (GST) in which the caspase-1 cleavage site was mutated into a Factor Xa cleavage site. Following purification on glutathione agarose, mature human IL-18 was cleaved by Factor Xa. 22 Human recombinant histidine-tagged IL-18BPa (rIL18BPa-His 6 ) was prepared in CHO cells and purified on a Talon column (Promega, Madison, WI) followed by a monoclonal anti 6 hisidine tag antibody column (R&D systems, Minneapolis, MN). A rabbit was injected with this preparation of rIL-18BPa-His 6 for the generation of polyclonal antibodies. Another aliquot of this preparation was iodinated by a modification of the Chloramine T method to a specific activity of 10 5 cpm/ng. Recombinant (non-tagged) IL-18BPa (rIL-18BPa) was prepared in CHO cells and purified by immunoaffinity chromatography using a Protein G-purified MAb no.430 (see Table 1 ) followed by size exclusion HPLC on a Superdex 75 column (Amersham-Pharmacia Biotech, Uppsala, Sweden). Human IL-18BP-His 6 isoforms b, c and d and murine IL-18BP-His 6 isoforms c and d were transiently expressed in COS 7 cells and purified on Talon column. 19 Pro IL-18 was from R&D Systems; IL-1 and proIL-1 were from Cistron Biotechnology, (Pinebrook, NJ). Affinity-purified goat anti-mouse F(ab) 2 antibody (Jackson ImmunoResearch Labs, West Grove, PA) was iodinated by a modification of the Chloramine T method to a specific activity of 4 10 4 cpm/ng.
Preparation of monoclonal antibodies to IL-18BPa
Two groups of female Balb/C mice were injected five times with 10 g of either rIL-18BPa-His 6 or rIL-18-BPa. In each group, the mouse exhibiting the highest binding titer as determined by an inverted radioimmunoassay (IRIA) or solid phase RIA (sRIA, see below) was given a final boost intraperitoneally four and three days, respectively, before fusion. Lymphocytes were prepared from both the spleen and lymph nodes of the mice and two separate fusion procedures to NSO/l myeloma cells were performed. Hybridomas that were found to produce antibodies to IL-18BPa were subcloned by the limiting dilution method and injected into Balb/C mice that had been primed with pristane for the production of ascites. The isotypes of the antibodies were defined with the use of an anti-mouse IgG ELISA (Amersham-Pharmacia Biotech).
Screening of positive clones by inverted radioimmunoassay (IRIA) with goat anti-mouse antibodies as the capture step
Anti-rIL-18BPa-His 6 hybridoma supernatants were screened for the presence of anti-IL-18BPa antibodies by IRIA. Briefly, PVC microtiter plates (Dynatech Laboratories, Alexandria, VA) were coated overnight at 4 C with affinity-purified goat anti-mouse F(ab) 2 antibodies (10 g/ml, l00 l/well; Jackson ImmunoResearch Labs). The plates were then washed twice with PBS containing 0.05% (w/v) Tween 20 (washing solution) and blocked with BSA (0.5% in washing solution) for two hours at 37 C. Hybridoma culture supernatants (100 l/well) were added and the plates were incubated for two hours at room temperature. The plates were washed three times, recombinant 125 I-rIL-18BPa-His 6 (10 5 cpm in 100 l) was added to each well and the plates were incubated for five hours at room temperature. The plates were then washed three times and individual wells were cut and counted in a gamma counter. Hybridomas with counts five-fold higher than the negative control were considered positive.
Screening of positive clones by solid phase RIA (sRIA) with rIL-18BPa or urinary IL-18BP as the capture step
MAbs against the rIL-18BPa were screened by sRIA in which rIL-18BPa (5 g/ml) was used as the capture antigen and 125 I-goat anti-mouse antibodies (100 l, 10 5 cpm) were used for detection. Blocking and washings were done as above. Positive clones were further screened by sRIA for their ability to recognize the IL-18BPa isolated from concentrated human urine.
14 Microtiter plates were coated with ligand-affinity purified urinary IL-18BP (1 g/ml), blocked and washed as above. Hybridoma supernatants (100 l) were added and detection was done with 125 I-goat anti-mouse antibodies (10 5 cpm in 100 l).
Screening by sRIA for antibodies that block the ligand binding site of IL-18BP
Microtiter plates were coated with either urinary IL-18BP (0.5 g/ml) or rIL-18BPa, blocked and washed as in sRIA. Recombinant human IL-18 (50 l) was added to a final concentration of 1.5 g/ml (15 min at room temperature), followed by the addition of hybridoma supernatants (50 l). Detection was done with 125 I-goat anti-mouse antibodies (10 5 cpm in 100 l, two hours at room temperature).
Screening for ELISA pairs
Microtiter plates were coated with a panel of Protein G Sepharose-purified MAbs.
125 I-IL-18BPa (100 l, 10 5 cpm) was incubated for two hours at room temperature in the presence or in the absence of the same panel of antibodies (1 g/ml) and then added to the coated wells (four hours at room temperature). Blocking and washings were done as described for the IRIA. A signal was observed only when the capture antibody and the detection antibody were directed against different epitopes of the IL-18BPa molecule. Coating of wells was verified with 125 I-goat anti-mouse antibodies (100 l, 10 5 cpm).
ELISA 1 (a sandwich of monoclonal and polyclonal antibodies) for the detection of human IL-18BPa
Microtiter 96-well ELISA plates (Maxisorb; Nunc A/S, Roskilde, Denmark) were coated with anti IL-18BPa MAb no. 582.10 (a subclone of anti-rIL-18BPa-His 6 MAb 582, 4 g/ml in PBS) overnight at 4 C. The plates were washed with PBS containing 0.05% Tween 20 (washing solution) and blocked (two hours, 37 C) with bovine serum albumin (BSA) stock solution (KPL, Geithersburg, MD) diluted 1:10 in water. BSA stock solution was diluted 1:15 in water (diluent) for the dilution of all tested samples and the detecting antibody. Sera to be tested for IL-18BPa concentration were diluted at least 1:5 in the diluent and 100 l aliquots were added to the wells. rIL-18BPa purified to homogeneity was diluted by seven serial twofold dilutions (4 ng/ml to 0.062 ng/ ml) and added to each ELISA plate for the generation of a standard curve. The plates were incubated for two hours at 37 C and then washed three times with the washing solution. Rabbit anti rIL-18BPa-His 6 serum (1:5000 in diluent, 100 1/ well) was then added and the plates were further incubated for two hours at 37 C. The plates were then washed three times, a conjugate of goat-anti-rabbit horseradish peroxidase (HRP, Jackson ImmunoResearch Labs, 1:10 000 in PBS, 100 l/well) was added and the plates were incubated for one hour at 37 C. The plates were then washed three times and developed by the addition of OPD Peroxidase substrate (o-phenylenediamine dihydrochloride tablets, Sigma) for 30 min at room temperature. The reaction was stopped by 3N HCl (100 l) and the absorbance at 492 nm was determined by an ELISA reader.
ELISA 2 (double MAb) for human IL-18BPa
Microtiter ELISA plates were coated (overnight at 4 C) with anti rIL-18BPa MAb 657.27 (a subclone of 657, 4 g/ml in PBS). Detection was done by a biotinylated 23 anti-rIL18BPa-His 6 MAb no. 582.10 (0.5 g/ml), followed by HRPstreptavidin (Pierce, Rockville, IL 1:10 000). Blocking, washing, handling of samples and incubation times were carried out as described above for ELISA 1.
ECL assay for IL-18
The ECL assay 24 for measuring various cytokines has been described previously. 25 For IL-18 measurements, two antibodies to human IL-18 were purchased from R&D Systems. A mouse monoclonal anti human IL-18 antibody was biotinylated and an affinity-purified rabbit anti human IL-18 polyclonal antibody was ruthenylated (Igen, Inc., Gaithersburg, MD). Magnetic beads (Dynal Corp. Lake Success, NY) coated with streptavidin (25 l suspension) were mixed with the biotinylated antibody (25 l, 1 g/ml) and the sample to be measured (25 l) was added. The mixture was agitated for 18 h at room temperature. The ruthenylated antibody (25 l, 1 g/ml) was then added and agitated for two hours. The beads complexed with the cytokine were separated from the reaction mixture and washed in an automated analyzer (Origen, Igen). The ruthenium was chemically activated to an excited state and the resulting chemiluminescence was measured. A standard curve was constructed using recombinant human IL-18 (R&D Systems) diluted in ECL buffer (0.25% BSA, Sigma, in PBS containing 2% Tween 20) containing 50% pooled human serum. The standard curve ranged from 20 pg/ml to 4.0 ng/ ml. The correlation coefficient between the ECL assay and a commercial EL1SA for IL-18 (R&D Systems), was 0.89 (performed with 29 serum samples).
IL-18 and IL-18BPa in septic patients
Sera were obtained as part of a previous study on the effect of infusion of intravenous Ig for the treatment of sepsis syndrome and acute renal failure. The entry and exclusion criteria for that study has been described. 26 Clinical assessment at entry into the study was made using the acute physiologic and health evaluation score (APACHE II). 27 Serum samples were initially aliquoted and kept frozen at 70 C until assayed. Upon thawing, sera were clarified by centrifugation at 10 000 rpm before the assay. Levels of IL-18 and IL-18BPa were measured on the admission sample of 42 patients and on samples obtained two to 10 days after admission. A total of 198 samples were subjected to analysis. The creatinine level in each sample was also determined.
Calculation of free IL-18
Free IL-18 was determined according to the law of mass action. The calculation was based on the following parameters: the concentrations of total IL-18 as determined by the ECL assay; the concentration of total IL-18BPa as determined by the present EL1SA; a 1:1 stoichiometry in the complex of IL-18 and IL-18BPa and a dissociation constant (K d ) of 0.4 nM. 14, 19 
